Merck Settles Patent Dispute Over Keytruda for $625 M plus Royalties

By February 8, 2017 Generic Line No Comments

Merck has agreed to pay Bristol Myers Squibb and Ono Pharmaceutical $625 million, plus royalties on global Keytruda sales, to resolve patent-infringement allegations involving an antibody designed to treat cancer by reactivating the body’s anti-tumor immune response.
Source: Generic Line